表紙
市場調查報告書
商品編碼
1034707

TRK抑制劑的全球市場:醫藥品銷售、臨床實驗的考察 (2026年)

Global TRK Inhibitors Market, Drug Sales & Clinical Trials insight 2026

出版日期: | 出版商: KuicK Research | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

目前,由於兩種藥物的獲批,全球TRK抑製劑市場正處於起步階段。然而,預計未來幾年市場將出現巨大的成長,這主要是由於癌症患病率增加和對靶向治療的需求未取得滿足。除此之外,對藥物可用性意識的提高、即將批准的新藥以及政府舉措增加也將推動市場的成長。

本報告提供全球TRK抑制劑市場相關分析,產品的概要和效果,整體市場規模趨勢預測 (2020年∼2026年),各地區、各適應症詳細趨勢,已上市產品 (2種)的專利、價格、銷售趨勢,目前臨床實驗的進展 (各相、各狀況、各地區),主要的推動及阻礙市場要素,主要企業的簡介競爭情形等彙整資訊。

目錄

第1章 原肌球蛋白受體激酶 (TRK) 抑制劑:簡介

  • TRK抑制劑概要
  • TRK抑制劑的演進

第2章 TRK:癌症治療潛在的標的

第3章 TRK抑制劑的作用機制

第4章 全球TRK抑制劑市場分析

  • 市場概要
  • 目前市場趨勢

第5章 TRK抑制劑市場:各地區分析

  • 美國
  • 歐洲
  • 日本
  • 其他的國家 (RoW)

第6章 TRK抑制劑市場:各適應症

  • 肺癌症
  • 乳癌
  • 結腸直腸癌症
  • 乳頭書甲狀腺癌症
  • 神經膠質母細胞瘤

第7章 Vitrakvi (Larotrectinib):最初已批准TRK抑制劑

  • 概要
  • 專利和受讓人

第8章 Vitrakvi (Larotrectinib):市場資訊

  • 價格趨勢
  • 銷售量分析

第9章 第Rozlytrek (Entrectinib):2號已批准TRK抑制劑

  • 概要
  • 專利和受讓人

第10章 Rozlytrek (Entrectinib):市場資訊

  • 價格、劑量分析
  • 銷售量分析

第11章 TRK抑制劑的銷售額預測2026年

  • Vitrakvi的銷售量的預測
  • Rozlytrek的銷售量的預測

第12章 在臨床實驗階段的主要TRK抑制劑

  • Selitrectinib
  • Repotrectinib
  • Taletrectinib
  • VMD928
  • ICP723
  • CHC2014

第13章 全球TRK抑制劑的臨床實驗平台 (各藥物)的分析

  • 調查
  • 前臨床
  • 第一階段
  • 第一/二階段
  • 第二階段
  • 第三階段

第14章 市售的TRK抑制劑:臨床性考察

第15章 全球TRK抑制劑的臨床實驗平台 (各實驗/研究) 洞察

  • 各相 (各期)
  • 各狀況
  • 各地區

第16章 全球TRK抑制劑市場未來展望

第17章 全球TRK抑制劑的市場動態

  • 市場促進因素
  • 市場課題

第18章 競爭情形

  • AstraZeneca
  • Aum Biosciences
  • Bayer
  • CMG Pharmaceutical
  • Eli Lilly & Company
  • InnoCare
  • Loxo Oncology
  • Ono Pharmaceutical
  • Pfizer
  • Roche
  • Turning Point Therapeutics
目錄

“Global TRK Inhibitors Market, Drug Sales & Clinical Trials Insight 2026 ” Report Analysis & Data Highlights:

  • Research Methodology
  • Global & Regional Market Analysis
  • Global TRK Inhibitors Market Opportunity Assessment: > USD 2 Billion
  • Market & Drug Sales Insight 2020 Till 2026
  • Approved Drug In Market: 2 Drugs
  • Approved TRK Drug Patent, Price & Sales insight 2020 Till 2026
  • Future Market Assessment By Indication Till 2026
  • Ongoing Clinical Trials Assessment by Status, Phase & Region
  • Key Market Dynamics
  • Competitor Landscape

The advancement in the field of biotechnology has promoted the recognition of the presence of targetable genomic alterations across multiple tumor types. Lately, researchers have identified NTRK gene fusions involving NTRK1, NTRK2, or NTRK3 encoding the neurotropin receptors TRKA, TRKB, and TRKC respectively as the oncogenic driver in several adult and pediatric cancers. Their critical role in the development, progression, and metastasis of cancer has made it potential target as an alternative for the treatment for the cancer. Since then, researchers have indulged in several research and development activities for the development of effective TRK inhibitors.

Currently, two TRK inhibitors including Vitrakvi and Rozlytrek have gained approval bodies for the management of NTRK positive solid tumors. The commercial launch of these drugs in the market has shown to completely transform the paradigm treatment of NTRK positive cancer. Since their introduction into the market, these drugs have shown high adoption rates which is mainly attributed to their high specificity and selectivity to NTRK genes, and its ability to overcome the limitation of conventional cancer therapies. Apart from this, these drugs have shown to cross the blood brain barrier, thus indicating its potential role in brain tumors.

In addition to approved drugs, the global pipeline of TRK inhibitors is highly crowded which suggests a brighter future of these inhibitors. The other TRK inhibitors in the pipeline are mainly developed to overcome the resistance to first generation TRK inhibitors. Selitrectinib (LOXO-195) and Repotrectinib (TPX-005) are the two next generation TRK inhibitors which have efficacy against TRK with acquired resistance. Currently, these are present in phase-II clinical trial and are expected to enter the market during the forthcoming years. Furthermore, several other potential candidates including Taletrectinib, VMD928, ICP723, and CHC2014 are also present in early phase of clinical trials and have shown promising preclinical activities.

The overall TRK inhibitor market is highly competitive and the key players working in market are AstraZeneca, Pfizer, Bayer, Loxo Oncology, Innocare, Ono Pharmaceutical, and Turning Point Therapeutics. The pharmaceutical giants have adopted several strategies to remain at forefront including agreement, mergers, joint ventures, collaboration, or acquisitions. For instance in May, 2021 AUM Biosciences entered into collaboration agreement with Handok and CMG Pharmaceutical for the worldwide development, manufacturing, and commercialization rights of CHC2014 which is highly specific and efficacious pan-TRK inhibitor.

Currently, the global TRK inhibitor market is present at nascent stage owing to the approval of two drugs. However, it is expected that the coming years will witness tremendous growth rates in the market which is mainly due to increase in prevalence of cancer and the unmet need for the targeted therapy. Apart from this, the increase in awareness about the availability of drugs, upcoming new drugs approval, and rise in government initiatives will also boost the growth of market.

United States is anticipated to have a dominant share in the market during the forecast period, due to rise in awareness about new drugs for treatment, availability of all major companies in the region, the introduction of new drugs, and high prevalence of cancer in the region. Apart from this, the presence of favorable reimbursement policies including Vitrakvi Co-Pay by Bayer or Rozlytrek Co-Pay by Genentech to reduce the out of pocket cost associated with drugs will also increase the adoption rates of TRK inhibitor drugs in the region.

The report provides insights into the patent, price, dosage and sales analysis of the currently approved TRK inhibitors. On the basis of indication, the market is segment into lung, colorectal, breast, glioblastoma and papillary thyroid cancer. Keeping in mind the various driver and challenges, the future outlook of TRK inhibitors has also been analyzed in the report.

Table of Contents

1. Introduction to Tropomyosin Receptor Kinase (TRK) Inhibitors

  • 1.1. Overview to TRK Inhibitors
  • 1.2. Evolution of TRK Inhibitors

2. TRK - Potential Target in Cancer Therapy

3. TRK Inhibitors Mechanism of Action

4. Global TRK Inhibitor Market Insight

  • 4.1. Market Overview
  • 4.2. Current Market Trends

5. TRK Inhibitors Market Regional Analysis

  • 5.1. US
  • 5.2. Europe
  • 5.3. Japan
  • 5.4. Rest of World

6. TRK Inhibitors Market by Indication

  • 6.1. Lung Cancer
  • 6.2. Breast Cancer
  • 6.3. Colorectal Cancer
  • 6.4. Papillary Thyroid Cancer
  • 6.5. Glioblastoma

7. Vitrakvi (Larotrectinib) - First Approved TRK Inhibitor

  • 7.1. Overview
  • 7.2. Patents & Assignees

8. Vitrakvi (Larotrectinib) - Commercial Information

  • 8.1. Pricing
  • 8.2. Sales Analysis

9. Rozlytrek (Entrectinib) - Second Approved TRK Inhibitor

  • 9.1. Overview
  • 9.2. Patents & Assignees

10. Rozlytrek (Entrectinib) - Commercial Information

  • 10.1. Price & Dosage Anlaysis
  • 10.2. Sales Analysis

11. TRK Inhibitors Sales Forecast 2026

  • 11.1. Vitrakvi Sales Forecast
  • 11.2. Rozlytrek Sales Forecast

12. Key TRK Inhibitors Drugs in Clinical Development

  • 12.1. Selitrectinib
  • 12.2. Repotrectinib
  • 12.3. Taletrectinib
  • 12.4. VMD928
  • 12.5. ICP723
  • 12.6. CHC2014

13. Global TRK Inhibitors Clinical Pipeline (By Drugs) Insight

  • 13.1. Research
  • 13.2. Preclinical
  • 13.3. Phase-I
  • 13.4. Phase-I/II
  • 13.5. Phase-II
  • 13.6. Phase-III

14. Marketed TRK inhibitors Clinical Insight

15. Global TRK Inhibitors Clinical Pipeline (By Trials/Studies) Insight

  • 15.1. By Phase
  • 15.2. By Status
  • 15.3. By Region

16. Global TRK Inhibitors Market Future Outlook

17. Global TRK Inhibitor Market Dynamics

  • 17.1. Market Drivers
  • 17.2. Market Challenges

18. Competitive Landscape

  • 18.1. AstraZeneca
  • 18.2. Aum Biosciences
  • 18.3. Bayer
  • 18.4. CMG Pharmaceutical
  • 18.5. Eli Lilly & Company
  • 18.6. InnoCare
  • 18.7. Loxo Oncology
  • 18.8. Ono Pharmaceutical
  • 18.9. Pfizer
  • 18.10. Roche
  • 18.11. Turning Point Therapeutics

List of Figures

  • Figure 1-1: Resistance Mechanism in First Generation TRK Inhibitors
  • Figure 1-2: Development Timeline of TRK Inhibitors
  • Figure 2-1: Neurotrophins & Their Receptors
  • Figure 2-2: Role of TRK Signaling in Cancer
  • Figure 3-1: TRK Inhibitors - Mechanism of Action
  • Figure 4-1: Global - Cancer Incidences & Deaths (Million), 2020 & 2025
  • Figure 4-2: Global - TRK Inhibitors Market by Product (US$ Million), 2020
  • Figure 4-3: Global - TRK Inhibitors Market by Product (%), 2020
  • Figure 4-4: Global - TRK Inhibitors Market by Product (US$ Million), Q1, 2021
  • Figure 4-5: Global - TRK Inhibitors Market by Product (US$ Million), Q2, 2021
  • Figure 4-6: Global - TRK Inhibitors Market by Product (US$ Million), H1, 2021
  • Figure 4-7: Global - TRK Inhibitors Market by Product (%), H1, 2021
  • Figure 4-8: Global - TRK Inhibitor Market Size (US$ Million), 2020 - 2026
  • Figure 4-9: TRK Inhibitor - Market by Region (US$ Million), 2020
  • Figure 4-10: TRK Inhibitors Market by Region (%), 2020
  • Figure 5-1: US - Cancer Incidences & Deaths (Million), 2020 & 2025
  • Figure 5-2: TRK Inhibitor Market - US vs. ROW (US$ Million), 2020
  • Figure 5-3: TRK Inhibitor Market - US vs. ROW (%), 2020
  • Figure 5-4: US - TRK Inhibitors Market by Product (US$ Million), 2020
  • Figure 5-5: US - TRK Inhibitors Market by Product (%), 2020
  • Figure 5-6: US - TRK Inhibitors Market by Product (US$ Million), H1, 2021
  • Figure 5-7: US - TRK Inhibitors Market by Product (%), H1, 2021
  • Figure 5-8: US - TRK Inhibitor Market Size (US$ Million), 2020 - 2026
  • Figure 5-9: Europe - Cancer Incidences & Deaths (Million), 2020 & 2025
  • Figure 5-10: Europe - Cancer Incidences by Country (Million), 2020
  • Figure 5-11: TRK Inhibitor Market - Europe vs. ROW (US$ Million), 2020
  • Figure 5-12: TRK Inhibitor Market - Europe vs. ROW (%), 2020
  • Figure 5-13: Europe - TRK Inhibitors Market by Product (US$ Million), 2020
  • Figure 5-14: Europe - TRK Inhibitors Market by Product (%), 2020
  • Figure 5-15: Europe - TRK Inhibitors Market by Product (US$ Million), H1, 2021
  • Figure 5-16: Europe - TRK Inhibitors Market by Product (%), H1, 2021
  • Figure 5-17: Europe - TRK Inhibitor Market Size (US$ Million), 2020 - 2026
  • Figure 5-18: Japan - Cancer Incidences & Deaths (Million), 2020 & 2025
  • Figure 5-19: TRK Inhibitors Market - Japan vs. ROW (US$ Million), 2020
  • Figure 5-20: TRK Inhibitors Market - Japan vs. ROW (%), 2020
  • Figure 5-21: Japan - TRK Inhibitors Market by Product (US$ Million), 2020
  • Figure 5-22: Japan - TRK Inhibitors Market by Product (%), 2020
  • Figure 5-23: Japan - TRK Inhibitors Market by Product (US$ Million), H1, 2021
  • Figure 5-24: Japan - TRK Inhibitors Market by Product (%), H1, 2021
  • Figure 5-25: Japan - TRK Inhibitor Market Size (US$ Million), 2020 - 2026
  • Figure 5-26: China - Cancer Incidences & Deaths (Million), 2020 & 2025
  • Figure 5-27: South Korea - Cancer Incidences & Deaths, 2020 & 2025
  • Figure 5-28: TRK Inhibitors Market - China vs. ROW (%), 2020
  • Figure 5-29: ROW - TRK Inhibitors Market by Product (US$ Million), H1, 2021
  • Figure 5-30: ROW - TRK Inhibitors Market by Product (%), H1, 2021
  • Figure 5-31: ROW - TRK Inhibitors Market Size (US$ Million), 2020 - 2026
  • Figure 6-1: Global - Lung Cancer Incidences, 2020 - 2026
  • Figure 6-2: Global - Non-Small Cell Lung Cancer Incidences, 2020 - 2026
  • Figure 6-3: Global - NTRK Positive Lung Cancer Incidences, 2020 - 2026
  • Figure 6-4: Global - NTRK Positive Non-Small Cell Lung Cancer Incidences, 2020 - 2026
  • Figure 6-5: Global - Breast Cancer Incidences, 2020 - 2026
  • Figure 6-6: Global - NTRK Positive Breast Cancer Incidences, 2020 - 2026
  • Figure 6-7: Global - Colorectal Cancer Incidences, 2020 - 2026
  • Figure 6-8: Global - NTRK Positive Colorectal Cancer Incidences, 2020 - 2026
  • Figure 6-9: Global - Thyroid Cancer Incidences, 2020 - 2026
  • Figure 6-10: Global - Papillary Thyroid Cancer Incidences, 2020 - 2026
  • Figure 6-11: Global - NTRK Positive Papillary Thyroid Cancer Incidences, 2020 - 2026
  • Figure 6-12: Global - Brain Cancer Incidences, 2020 - 2026
  • Figure 6-13: Global - Gliomlastoma Incidences, 2020 - 2026
  • Figure 6-14: Global - NTRK Positive Gliolastoma Incidences, 2020 - 2026
  • Figure 7-1: US - Vitrakvi Orphan Status & FDA Approval Year
  • Figure 7-2: Vitrakvi - Approval Year by Region
  • Figure 7-3: US - Vitrakvi Patent Approval & Expiration Year
  • Figure 7-4: US - Vitrakvi Patents by Assignees
  • Figure 8-1: US - Cost of Supply of 60 Capsules & Per Unit Cost of Virtakvi 25mg Capsules (US$), October'2021
  • Figure 8-2: US - Cost of Supply of 60 Capsules & Per Unit Cost of Virtakvi 100mg Capsules (US$), October'2021
  • Figure 8-3: US - Cost of Supply of 100ml & Per Unit Cost of Virtakvi 20mg/ml Oral Solution (US$), October'2021
  • Figure 8-4: UK - Cost of Supply of 56 Capsules & Per Unit Cost of Virtakvi 25mg Capsules (Euro/US$), October'2021
  • Figure 8-5: UK - Cost of Supply of 60 Capsules & Per Unit Cost of Virtakvi 100mg Capsules (Euro/US$), October'2021
  • Figure 8-6: UK - Cost of Supply of 100ml & Per Unit Cost of Virtakvi 20mg/ml Oral Solution (Euro/US$), October'2021
  • Figure 8-7: Virtakvi - Recommended Initial & Dose Reductions in Adult/Pediatric Patients with at Least 1.0 Meter-Squared (mg)
  • Figure 8-8: Virtakvi - Recommended Initial & Dose Reductions in Pediatric Patients with Less than 1.0 Meter-Squared (mg/m2)
  • Figure 9-1: US - Rozlytrek Orphan Drug Designations Approval by Indication
  • Figure 9-2: Japan - Rozlytrek Approval Year by Indication
  • Figure 9-3: Rozlytrek - Approval Year by Region
  • Figure 9-4: US - Rozlytrek Patent Approval & Expiration Year
  • Figure 10-1: US - Cost of Supply of 30 Capsules & Per Unit Cost of Rozlytrek 100mg Capsules (US$), October'2021
  • Figure 10-2: US - Cost of Supply of 90 Capsules & Per Unit Cost of Rozlytrek 200mg Capsules (US$), October'2021
  • Figure 10-3: UK - Cost of Supply of 30 Capsules & Per Unit Cost of Rozlytrek 100mg Capsules (Euro/US$), October'2021
  • Figure 10-4: UK - Cost of Supply of 90 Capsules & Per Unit Cost of Rozlytrek 200mg Capsules (Euro/US$), October'2021
  • Figure 10-5: Rozlytrek - Recommended Initial & Dose Reductions in Adult/Pediatric Patients with BSA Greater than 1.50 m2 (mg/day)
  • Figure 10-6: Rozlytrek - Recommended Initial & Dose Reductions in Pediatric Patients with BSA of 1.11 to 1.50 m2 (mg/day)
  • Figure 10-7: Rozlytrek - Recommended Initial & Dose Reductions in Pediatric Patients with BSA of 0.91 to 1.1 m2 (mg/day)
  • Figure 10-8: Global - Rozlytrek Annual Sales (CHF/US$ Million), 2019 & 2020
  • Figure 10-9: US - Rozlytrek Annual Sales (CHF/US$ Million), 2019 & 2020
  • Figure 10-10: Rozlytrek - Annual Sales by Region (CHF/US$ Million), 2020
  • Figure 10-11: Rozlytrek - Annual Sales by Region (%), 2020
  • Figure 10-12: Global - Rozlytrek Quarterly Sales (CHF/US$ Million), 2020
  • Figure 10-13: Global - Rozlytrek Quarterly Sales (CHF/US$ Million), Q1 & Q2'2021
  • Figure 10-14: Rozlytrek -Sales by Region (CHF/US$ Million), Q1'2021
  • Figure 10-15: Rozlytrek - Sales by Region (CHF/US$ Million), Q2'2021
  • Figure 10-16: Rozlytrek - Half Year Sales by Region (CHF/US$ Million), H1'2021
  • Figure 10-17: Rozlytrek - Half Year Sales by Region (%), H1'2021
  • Figure 11-1: Global - Vitrakvi Sales Forecast (US$ Million), 2021 - 2026
  • Figure 11-2: Global - Rozlytrek Sales Forecast (US$ Million), 2021 - 2026
  • Figure 11-3: US - Rozlytrek Sales Forecast (US$ Million), 2021 - 2026
  • Figure 11-4: Europe - Rozlytrek Sales Forecast (US$ Million), 2021 - 2026
  • Figure 11-5: Japan - Rozlytrek Sales Forecast (US$ Million), 2021 - 2026
  • Figure 11-6: ROW - Rozlytrek Sales Forecast (US$ Million), 2021 - 2026
  • Figure 12-1: Selitrectinib - Phase-I/II Clinical Study Initiation & Primary Completion Year
  • Figure 12-2: Taletrectinib - Phase-II Clinical Study Initiation & Primary Completion Year
  • Figure 12-3: VMD928 - Phase-I Clinical Study Initiation & Primary Completion Year
  • Figure 12-4: ICP723 - Phase-I/II Clinical Study Initiation & Primary Completion Year
  • Figure 13-1: Global TRK Inhibitors Clinical Pipeline insight (Number of drugs), 2021 till 2026
  • Figure 15-1: Global - TRK Inhibitor Clinical Trials Insight by Phase (Number of Trials), October'2021
  • Figure 15-2: Global - TRK Inhibitor Clinical Trials Insight by Phase (%),October'2021
  • Figure 15-3: Global - TRK Inhibitor Clinical Trials Insight by Status (Number of Trials), October'2021
  • Figure 15-4: Global - TRK Inhibitor Clinical Trials Insight by Status (%),October'2021
  • Figure 15-5: TRK Inhibitor - Clinical Trials Insight by Region (Number of Trials), October'2021
  • Figure 15-6: North America - Clinical Trial by Countries, October'2021
  • Figure 15-7: TRK Inhibitor - Clinical Trials Insight by Region, October'2021
  • Figure 15-8: North America - Clinical Trial by Countries (%),October'2021
  • Figure 17-1: Global - Cancer Incidences & Deaths (Million), 2020 & 2040
  • Figure 17-2: Global - TRK Inhibition Market Drivers
  • Figure 17-3: Global - TRK Inhibitor Market Challenges